134 related articles for article (PubMed ID: 38220151)
21. A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.
Cherniawsky H; Merchant N; Sawyer M; Ho M
Medicine (Baltimore); 2017 Feb; 96(8):e5850. PubMed ID: 28225482
[TBL] [Abstract][Full Text] [Related]
22. Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report.
Jayaweera JL; Withana MR; Dalpatadu CK; Beligaswatta CD; Rajapakse T; Jayasinghe S; Chang T
J Med Case Rep; 2014 Dec; 8():442. PubMed ID: 25519913
[TBL] [Abstract][Full Text] [Related]
23. H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.
Jamali NS; Raja Sabudin RZA; Alauddin H; Ithnin A; Tumian NR; Jalil N; Awai R; Abu Amis SH; Shuib S
Malays J Pathol; 2021 Apr; 43(1):63-68. PubMed ID: 33903307
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.
Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M
Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995
[TBL] [Abstract][Full Text] [Related]
25. Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature.
Racchiusa S; Mormina E; Ax A; Musumeci O; Longo M; Granata F
Neurol Sci; 2019 May; 40(5):915-922. PubMed ID: 30604335
[TBL] [Abstract][Full Text] [Related]
26. Posterior reversible encephalopathy syndrome with extensive cytotoxic edema after blood transfusion: a case report and literature review.
Nakamura Y; Sugino M; Tsukahara A; Nakazawa H; Yamamoto N; Arawaka S
BMC Neurol; 2018 Nov; 18(1):190. PubMed ID: 30419835
[TBL] [Abstract][Full Text] [Related]
27. Posterior Reversible Encephalopathy Syndrome Occurred During the Use of Pseudoephedrine: A Case Report.
Gunduz ZB
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):145-147. PubMed ID: 36066857
[TBL] [Abstract][Full Text] [Related]
28. Posterior reversible encephalopathy syndrome: 'a headache' on the AMU.
Desai P; Bholah MH; Dunn E
Acute Med; 2013; 12(1):26-9. PubMed ID: 23539373
[TBL] [Abstract][Full Text] [Related]
29. Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
Tsukamoto S; Takeuchi M; Kawajiri C; Tanaka S; Nagao Y; Sugita Y; Yamazaki A; Kawaguchi T; Muto T; Sakai S; Takeda Y; Ohwada C; Sakaida E; Shimizu N; Yokote K; Iseki T; Nakaseko C
Int J Hematol; 2012 Feb; 95(2):204-8. PubMed ID: 22160836
[TBL] [Abstract][Full Text] [Related]
30. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
31. Posterior Reversible Encephalopathy Syndrome Causing Vision Loss After Endoscopic Endonasal Resection of Pituitary Adenoma.
Villelli NW; Prevedello DM; Ikeda DS; Montaser AS; Otto BA; Carrau RL
World Neurosurg; 2017 Apr; 100():708.e1-708.e10. PubMed ID: 28214641
[TBL] [Abstract][Full Text] [Related]
32. Posterior reversible encephalopathy syndrome.
Yasuhara T; Tokunaga K; Hishikawa T; Ono S; Miyoshi Y; Sugiu K; Date I
J Clin Neurosci; 2011 Mar; 18(3):406-9. PubMed ID: 21236681
[TBL] [Abstract][Full Text] [Related]
33. [Nilotinib in patients with chronic myeloid leukemia without response to imatinib].
Báez-de la Fuente E; Arellano-Severiano B
Rev Med Inst Mex Seguro Soc; 2014; 52(3):330-3. PubMed ID: 24878095
[TBL] [Abstract][Full Text] [Related]
34. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
Yoshizato T; Nannya Y; Yoshiki Y; Nakamura F; Imai Y; Ichikawa M; Kurokawa M
Int J Hematol; 2011 Mar; 93(3):400-402. PubMed ID: 21347645
[TBL] [Abstract][Full Text] [Related]
35. Posterior reversible encephalopathy syndrome and systemic vasculitis: report of six cases.
Lioger B; Diot E; Ebbo M; Schleinitz N; Aaron L; Michot JM; Lambotte O; Dhote R; De Boysson H; Ponce E; Maillot F;
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S7-11. PubMed ID: 26412031
[TBL] [Abstract][Full Text] [Related]
36. Posterior reversible encephalopathy syndrome secondary to blood transfusion.
Singh K; Gupta R; Kamal H; Silvestri NJ; Wolfe GI
J Clin Neurosci; 2015 Mar; 22(3):592-4. PubMed ID: 25542590
[TBL] [Abstract][Full Text] [Related]
37. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
38. Posterior Reversible Encephalopathy Syndrome.
Gewirtz AN; Gao V; Parauda SC; Robbins MS
Curr Pain Headache Rep; 2021 Feb; 25(3):19. PubMed ID: 33630183
[TBL] [Abstract][Full Text] [Related]
39. Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation.
Barbas AS; Rege AS; Castleberry AW; Gommer J; Ellis MJ; Brennan TV; Collins BH; Martin AE; Ravindra KV; Vikraman DS; Sudan DL
Am J Transplant; 2013 Mar; 13(3):808-10. PubMed ID: 23331705
[TBL] [Abstract][Full Text] [Related]
40. Neuropathological findings from an autopsied case showing posterior reversible encephalopathy syndrome-like neuroradiological findings associated with premedication including tacrolimus for autologous peripheral blood stem cell transplantation.
Hayashi Y; Kimura A; Nakamura H; Mimuro M; Iwasaki Y; Hara A; Yoshida M; Inuzuka T
J Neurol Sci; 2017 Apr; 375():382-387. PubMed ID: 28320172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
